Journal
PHARMACEUTICS
Volume 14, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics14030562
Keywords
albumin fusion; thioredoxin; oxidative stress; inflammation; cardiomyopathy; doxorubicin
Categories
Funding
- Research Foundation for Pharmaceutical Sciences
- Japan Society for the Promotion of Science [15H04758, 16H05114]
- Takeda Science Foundation, Japan
- National Institute for Physiological Sciences [18-116, 19-111]
- Grants-in-Aid for Scientific Research [15H04758, 16H05114] Funding Source: KAKEN
Ask authors/readers for more resources
In this study, a long-acting Thioredoxin (Trx) was prepared by fusing human Trx with human serum albumin (HSA) and its efficacy in treating drug-induced heart failure was evaluated. The results showed that HSA-Trx administration suppressed the adverse effects of drug-induced cardiomyopathy, including heart weight decrease, myocardial fibrosis increase, and markers for myocardial damage. HSA-Trx also inhibited oxidative stress and inflammation, as well as the expression of myocardial atrophy factors. The findings suggest that HSA-Trx can improve the pathological condition associated with doxorubicin-induced cardiomyopathy.
Although the number of patients with heart failure is increasing, a sufficient treatment agent has not been established. Oxidative stress and inflammation play important roles in the development of myocardial remodeling. When thioredoxin (Trx), an endogenous anti-oxidative and inflammatory modulator with a molecular weight of 12 kDa, is exogenously administered, it disappears rapidly from the blood circulation. In this study, we prepared a long-acting Trx, by fusing human Trx (HSA-Trx) with human serum albumin (HSA) and evaluated its efficacy in treating drug-induced heart failure. Drug-induced cardiomyopathy was created by intraperitoneally administering doxorubicin (Dox) to mice three times per week. A decrease in heart weight, increased myocardial fibrosis and markers for myocardial damage that were observed in the Dox group were suppressed by HSA-Trx administration. HSA-Trx also suppressed the expression of atrogin-1 and myostatin, myocardial atrophy factors in addition to suppressing oxidative stress and inflammation. In the Dox group, a decreased expression of endogenous Trx in cardiac tissue and an increased expression of macrophage migration inhibitory factor were observed, but these changes were restored to normal levels by HSA-Trx administration. These findings suggest that HSA-Trx improves the pathological condition associated with Dox-induced cardiomyopathy by its anti-oxidative/anti-inflammatory and myocardial atrophy inhibitory action.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available